Influence of hepatic steatosis and metabolic syndrome on the response to antiviral pharmacological treatment in patients with chronic hepatitis B
DOI:
https://doi.org/10.47456/rbps.v25isupl_2.41000Keywords:
Chronic Hepatitis B, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Drug Therapy, Treatment OutcomeAbstract
Introduction: The influence of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) in the antiviral treatment of patients with chronic hepatitis B (CHB) is still unclear in the literature. The increased prevalence of these comorbidities in the general population may influence the antiviral response in patients with CHB. Objectives: Evaluate the influence of NAFLD and MS on the complete virological response (CVR) time in patients with CHB. Methods: Retrospective cross-sectional study in which patients with CHB were divided into two groups: without comorbidities (G1) and with NAFLD and/or MS (G2). After describing their clinical, epidemiological and biochemical characteristics, we evaluated the groups in two moments, at the beginning of antiviral therapy and at the moment when CVR was reached, comparing the time in months for both groups until negative results. Results: 65 patients were evaluated after exclusion criteria (G1:48; G2:17). After describing the population, it was possible to assess the profile of patients in the population and found a mean time until CVR in G1 of 10.5 months and in G2 of 14 months (p=0.019). Conclusion: The presence of NAFLD and/or MS delays the complete virological response in individuals being treated for chronic hepatitis B. The joint assessment of these comorbidities may benefit the therapeutic response in individuals with chronic hepatitis B.
Downloads
References
Alberti KGM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, Philip TJ, Loria CM, Smith SC. Harmo¬nizing the Metabolic Syndrome, Circulation, 2009; 120:1640-45.
Kahn R, Buse JMD, Ferrannini E, Stern M. The metabolic syn¬drome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28(9):2289–304.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Mymer M. Global epidemiology of nonalcoholic fatty liver disease-Me¬ta-analytic assessment of prevalence, incidence and outcomes. Hepatology 2016; 64(1):73-84.
Meneses I, Lima MÊS, Albuquerque MCF, Veloso AFH, Bachur TPR. Esteato-hepatite não alcoólica: uma síndrome em evidên¬cia, Braz. J. Hea. Rev, 2020; 3(1):1077-94
Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z. Global prevalence, treatment and preven¬tion of hepatitis B vírus infection in 2016: a modeling study. Lancet Gastroenterol Hepatol 2018; 3(6):383 – 403.
Benzaken AS, Razavi H, Schmelzer J, Razavi-shearer D, Pereira G, Catapan E. Hepatitis B Elimination in Brazil: revisiting the current strategy. Hepatology. 2019; 70(1):251-2.
Reuter TQ, Gouvea MG, Chuffi S, Duque UH, Carvalho JA, Per¬ini W, Queiroz MM, Segal IM, Azevedo RS, Pinho JRR. Hepati¬tis B virus genotypes and subgenotypes and the natural history and epidemiology of hepatitis B, Annals of Hepatology, 2022; 27:1665-81.
Miranda AEB, Pereira GFM. Boletim epidemiológico - Hepatites Virais, Secretaria de vigilância em saúde, MS. 2022.
Diao Y, Tang J, Wang X, Deng W, Tang J, You C. Metabolic Syn¬drome, Nonalcoholic Fatty Liver disease, and Chronic Hepatitis B: A Narrative Review, Infect Dis Ther. 2023; 12:53-66
NamHee k, Yong KC, Byung IK, Hong JK. Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment, Digestive Diseases and Sciences. 2018; 63:2792–9
Siyu Z, Xiaoxiao Z, Huiming J, Yao D, Lu L, Xiwei Y, Chen D, Mengmeng H, Yue-min N, Jia S. Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B, Journal of Clinical and Translational Hepa¬tology. 2023; 11(1):67-75
Chen J, Wang ML, Long Q, Bai L, Tang H. High value of con¬trolled attenuation parameter predicts a poor antiviral response in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2017;16(4):370–374.
Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chi¬nese patients with chronic hepatitis B. PLoS One. 2012;7(3):341- 98.
Wang MF, Bo W, Yin-Lian W, Jiao-Feng H, Yue-Yong Z, You- Bing Li. Clinic-pathological features od metabolic associated fatty liver disease with hepatitis B vírus infection, WJG. 2021; 27(4):336-344.
Huang S, Kao J. Metabolic dysfunction-associated fatty liver dis¬ease and chronic hepatitis B, JFMA. 2022; 121:2148-51.
Mak LY, Wan-Hin HR, Fung J, Liu F, Ka-Ho WD, Cheung KS, Yuen MF, Seto WK. Diverse effects of hepatic steatosis on fibro¬sis progression and functional cure in virologically quiescent chronic hepatitis B, Journal of Hepatology. 2020; 73(4):800-6.
Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Carcinoma hepatocelular: epidemiologia, biologia, diagnóstico e terapias, rev assoc med bras. 2013; 59(5):514–24.
Huang CY, Lu CW, Liu YL, Chiang CH, Lee LT, Huang KC. Relationship between chronic hepatitis B and metabolic syn¬drome: a structural equation modeling approach. Obesity. 2016; 24:483–9.
Yan LB, Liao J, Han N, Zhou LY, Wang XE, Wang YJ, Tang H. Association between hepatitis B virus infection and metabolic syndrome in Southwest China: a cross-sectional study. Sci Rep. 2020; 10:673-8.
Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS. Relationship between metabolic syndrome, alanine aminotrans¬ferase levels, and liver disease severity in a multiethnic North American cohort with chronic hepatitis B. Diabetes Care. 2018; 41:1251–9.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
